Catégories
Traitements innovants en toxicomanie

February 2021

This month, Violaine unveils the results of her randomized clinical trial involving cocaine users. Her study involved 78 participants with moderate to severe cocaine use disorder who went into a 10-day detoxification period before being weekly followed for 3 months. Participants were randomly assigned to daily receive a large dose (800 mg) of cannabidiol (CBD) or placebo for 92 days. Her results demonstrated that compared to placebo, CBD was unfortunately not effective in reducing cocaine craving, the risk of relapse or cocaine use. CBD was, however, well tolerated by participants and associated mainly with mild side effects such as diarrhea. Together, her results encourage the development of new pharmacological compounds to treat cocaine use disorder.

Catégories
Traitements innovants en toxicomanie

CBD-Cocaine

Participants wanted

Men and women consuming cocaine wishing to take medication during the study.

What was this study about?

This randomized, double-blind clinical trial (NCT0255967) investigated the efficacy of cannabidiol (vs. placebo) to treat cocaine dependence. It spanned a 14-week period and included a hospital detoxification phase (10 days) and a weekly follow-up phase (12 weeks).

To participate in one of our ongoing studies, please consult our directory.

See the infographic of our first results here or read the scientific article published in Addiction

Catégories
Traitements innovants en toxicomanie

OPTIMA Study

Participants wanted :

Men and women consuming opioids and wishing to access a substitution treatment.

What is OPTIMA?:

This randomized clinical trial (NCT03033732) consisted of comparing the effectiveness of two models of care for the management of opioid use. The first is methadone treatment and the second is buprenorphine/naloxone treatment.

Your role :

  • Attend follow-up visits every two weeks during 24-28 weeks
  • Fill out a questionnaire

You were not admissible if:

  • You have a contraindication to the medication used for this study
  • You are pregnant, breastfeeding or if you plan a pregnancy during the study
  • You are currently on agonist treatment (methadone or buprenorphine/naloxone)

To participate in one of our ongoing studies, please consult our directory.

Read the scientific article published in The American  Journal of Psychiatry

To see our knowledge transfer initiatives, please consult The OPTIMA Trial.